Summary
Quest Diagnostics Incorporated (DGX) filed an 8-K on November 16, 2009, reporting on significant financing activities. The company priced an underwritten public offering of $500 million in 4.750% Senior Notes due 2020 and $250 million in 5.750% Senior Notes due 2040. This offering, expected to close on November 17, 2009, is being conducted under an existing shelf registration statement and is projected to yield approximately $730 million in net proceeds. The net proceeds are earmarked for multiple strategic uses, including repurchasing notes tendered under a concurrent tender offer, general corporate purposes, potential acquisitions, capital expenditures, share repurchases, and repayment of other existing debt. The company also announced a tender offer for its outstanding 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011, indicating a proactive approach to managing its debt structure.
Key Highlights
- 1Quest Diagnostics priced a $750 million public offering of senior notes ($500 million due 2020 and $250 million due 2040).
- 2The offering includes notes with coupon rates of 4.750% (2020 maturity) and 5.750% (2040 maturity).
- 3Net proceeds from the offering are estimated to be approximately $730 million.
- 4Proceeds will be used for debt management, including repurchasing tendered notes, general corporate purposes, acquisitions, capital expenditures, and share repurchases.
- 5The company concurrently launched a tender offer to purchase all outstanding 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011.
- 6The financing activities are being conducted under an existing shelf registration statement (File No. 333-143867).
- 7The offering is expected to close on November 17, 2009.